Abstract
Cellular therapies have the potential to advance treatment for a broad array of diseases but rely on viruses for genetic reprogramming. The time and cost required to produce viruses has created a bottleneck that constricts development of and access to cellular therapies. Electroporation is a non-viral alternative for genetic reprogramming that bypasses these bottlenecks, but current electroporation technology suffers from low throughput, tedious optimization, and difficulty scaling to large-scale cell manufacturing. Here, we present an adaptable microfluidic electroporation platform with the capability for rapid, multiplexed optimization with 96-well plates. Once parameters are optimized using small volumes of cells, transfection can be seamlessly scaled to high-volume cell manufacturing without re-optimization. We demonstrate optimizing transfection of plasmid DNA to Jurkat cells, screening hundreds of different electrical waveforms of varying shapes at a speed of ~3 s per waveform using ~20 µL of cells per waveform. We selected an optimal set of transfection parameters using a low-volume flow cell. These parameters were then used in a separate high-volume flow cell where we obtained similar transfection performance by design. This demonstrates an alternative non-viral and economical transfection method for scaling to the volume required for producing a cell therapy without sacrificing performance. Importantly, this transfection method is disease-agnostic with broad applications beyond cell therapy.
Original language | English (US) |
---|---|
Article number | 10 |
Pages (from-to) | 10 |
Journal | Biomedical Microdevices |
Volume | 26 |
Issue number | 1 |
DOIs | |
State | Published - Jan 9 2024 |
Keywords
- Cancer
- Cell therapy
- Electroporation
- Immunotherapy
- Non-viral
- Transfection
- Electricity
- Humans
- Cell- and Tissue-Based Therapy
- Microfluidics
ASJC Scopus subject areas
- Molecular Biology
- Biomedical Engineering